175 related articles for article (PubMed ID: 29528252)
1. Candidate gene DNA methylation associations with breast cancer characteristics and tumor progression.
Kresovich JK; Gann PH; Erdal S; Chen HY; Argos M; Rauscher GH
Epigenomics; 2018 Apr; 10(4):367-378. PubMed ID: 29528252
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women.
Lee JS; Lo PK; Fackler MJ; Argani P; Zhang Z; Garrett-Meyer E; Sukumar S
Cancer Biol Ther; 2007 Jul; 6(7):1114-20. PubMed ID: 17611401
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women.
Mehrotra J; Ganpat MM; Kanaan Y; Fackler MJ; McVeigh M; Lahti-Domenici J; Polyak K; Argani P; Naab T; Garrett E; Parmigiani G; Broome C; Sukumar S
Clin Cancer Res; 2004 Mar; 10(6):2052-7. PubMed ID: 15041725
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation and hormone receptor status in breast cancer.
Benevolenskaya EV; Islam AB; Ahsan H; Kibriya MG; Jasmine F; Wolff B; Al-Alem U; Wiley E; Kajdacsy-Balla A; Macias V; Rauscher GH
Clin Epigenetics; 2016; 8():17. PubMed ID: 26884818
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
10. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
11. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
12. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
13. Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation.
Rauscher GH; Kresovich JK; Poulin M; Yan L; Macias V; Mahmoud AM; Al-Alem U; Kajdacsy-Balla A; Wiley EL; Tonetti D; Ehrlich M
BMC Cancer; 2015 Oct; 15():816. PubMed ID: 26510686
[TBL] [Abstract][Full Text] [Related]
14. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
[TBL] [Abstract][Full Text] [Related]
15. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
17. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Dunnwald LK; Rossing MA; Li CI
Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
[TBL] [Abstract][Full Text] [Related]
19. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
20. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
